RA Capital Management funds have significantly increased their exposure to Artiva Biotherapeutics, Inc., acquiring a total of $194,039 in common stock over a two-day period. The transactions, executed across July 2026, reflect a calculated accumulation of shares at prices ranging from $8.89 to $9.00. This institutional activity comes as Artiva Biotherapeutics navigates a period of heightened clinical and regulatory scrutiny, marked by recent advancements in its regenerative medicine pipeline.
The purchasing activity was documented on two distinct dates. On July 10, 2026, RA Capital Management funds acquired 15,102 shares of Artiva Biotherapeutics common stock. These shares were purchased at a weighted average price of $8.97 per share, with individual transaction prices fluctuating between $8.89 and $9.00. Subsequently, on July 13, 2026, an additional block of 6,552 shares was acquired. These later purchases were executed at a weighted average price of $8.94 per share, with transaction prices ranging from $8.89 to $8.95. The total value of these specific transactions amounted to $194,039.
These acquisitions were facilitated indirectly by RA Capital Healthcare Fund, L.P. RA Capital Management, L.P. acts as the investment manager for this fund, as well as for RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., and a separately managed account. Peter Kolchinsky and Rajeev Shah serve as managing members of RA Capital Management GP, LLC, the general partner of RA Capital Management, L.P. In accordance with regulatory disclosures, they, along with other reporting entities, disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Following these recent transactions, the institutional holdings within the RA Capital ecosystem have expanded. RA Capital Healthcare Fund, L.P. now holds 16,817,573 shares of common stock. Other indirect holdings within the fund family include 264,571 shares held by RA Capital Nexus Fund, L.P., 826,832 shares held by RA Capital Nexus Fund III, L.P., and 68,320 shares held by the separately managed account. Laura Stoppel, a Principal of RA Capital Management, L.P., continues to serve on Artiva Biotherapeutics’ board of directors, maintaining a governance link between the investor and the company.
The market has reacted with considerable momentum to Artiva Biotherapeutics. The stock currently trades at $9.35, reflecting a 329% increase over the past year. However, analysis indicates that the company appears overvalued at current levels relative to its Fair Value. The stock closed at 9.35, representing a +0.42 (+4.70%) movement, with after-hours trading showing a 9.54 price point, a +0.19 (+2.03%) change.
In other recent developments, Artiva Biotherapeutics received a significant boost as the FDA granted Regenerative Medicine Advanced Therapy designation to its AlloNK therapy in combination with rituximab for the treatment of refractory rheumatoid arthritis. This designation allows for expedited development and review processes, which could accelerate the therapy’s path to market. Additionally, Artiva presented promising clinical data at the European Alliance of Associations for Rheumatology Congress, showing that 71% of patients achieved an ACR50 response, indicating substantial improvement in their condition.
Analyst sentiment remains supportive, with Cantor Fitzgerald reiterating its Overweight rating on Artiva Biotherapeutics, maintaining a price target of $40.00, following a detailed review of the company’s strategy and clinical data. In a move to strengthen its leadership, Artiva announced executive changes, with Diego Miralles, M.D. resigning from the board to take on the role of President and Head of Research and Development. The board will now consist of seven members. These developments highlight Artiva’s ongoing efforts to advance its therapeutic offerings and strengthen its organizational structure.